# Chemed Corp: Form 10-Q for the period ended Mar 31, 2017

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2017-04-28
- Accepted by EDGAR: Apr 28, 2017, 07:58 ET
- Period: 2017-03-31
- Accession: 0001157523-17-001278
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000115752317001278/a51546341.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000115752317001278/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-01-01 to 2017-03-31 | $405.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2017-01-01 to 2017-03-31 | $285.1m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2017-01-01 to 2017-03-31 | $69.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | $41.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | $995.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-01-01 to 2017-03-31 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | $29.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | $1.78 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-01-01 to 2017-03-31 | $1.84 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 16,801,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months, 2017-01-01 to 2017-03-31 | $9.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2017-01-01 to 2017-03-31 | $4.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2017-01-01 to 2017-03-31 | $54.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-03-31 | $47.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $176.0m | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $886.2m | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $164.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $385.6m | us-gaap:Liabilities |
| Long-term debt | at 2017-03-31 | $137.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-03-31 | $9.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-03-31 | $500.6m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2017-03-31 | 16,082,181 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 34,760 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Service revenues and sales | **$405,864** | $390,389 |
| Net income | **$29,844** | $24,840 |
| Diluted EPS | **$1.78** | $1.45 |
| Adjusted net income | **$30,495** | $27,754 |
| Adjusted diluted EPS | **$1.82** | $1.62 |
| Adjusted EBITDA | **$59,818** | $54,480 |
| Adjusted EBITDA as a % of revenue | **14.7%** | 14.0% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 22-23.

For the three months ended March 31, 2017, the increase in consolidated service revenues and sales was driven by a 9.5% increase at Roto-Rooter and a 1.7% increase at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines. The increase in service revenues at VITAS was primarily a result of Medicare reimbursement rates increasing 1.6%, a 3.6% increase in average daily census, offset by acuity mix shift which negatively impacted revenue 2.4% and the 1.1% negative impact from having one less day in the quarter when compared to the prior year period. Consolidated net income increased 20.1% mainly due to increased revenue and gross profit margin at both VITAS and Roto-Rooter combined with a lower effective tax rate as a result of the adoption of ASU No. 2016-09. Diluted EPS increased 22.8% as a result of the increase in net income as well as a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue increased 70 basis points when compared to the prior year quarter mainly as a result of the increase in net income. See page 24 for additional VITAS operating metrics.

VITAS expects its full-year 2017 revenue growth, prior to Medicare cap, to be in the range of 4.0% to 5.0%. Admissions and Average Daily Census in 2017 is estimated to expand approximately 3.0% to 4.0%. Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.5% to 15.0%. This guidance includes $3.75 million for Medicare cap billing limitations. Roto-Rooter expects full-year 2017 revenue growth of 3.0% to 4.0%. The revenue estimate is a based upon increased job pricing of approximately 2.0% and continued growth in water restoration services. Adjusted EBITDA margin for 2017 is estimated in the range of 21.5% to 22.0%. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-14-

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2016 to March 31, 2017 include the following:

- A $22.3 million decrease in accounts receivable due mainly to timing of Medicare and Medicaid payments.
- We received a $41.7 million Medicare payment on March 31, 2017.
- A $10.2 million decrease in accounts payable due to timing of payments.
- A $12.6 million increase in income taxes payable due to timing of payments.
- A $6.2 million increase in accrued insurance primarily due to the change in stop loss receivable for the quarter.
- A $16.6 million decrease in accrued compensation due to the payments of cash bonuses accrued in 2016.
- A $38.1 million increase in long-term debt due to borrowings on our revolving line of credit mainly to fund stock repurchases.

Net cash provided by operating activities increased $61.6 million mainly as a result of a decrease in accounts receivable (causing an increase in cash) due to the timing of payments. We received a $41.7 million Medicare payment on March 31, 2017. Significant changes in our accounts receivable balances are typically driven mainly by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $40.0 million from the Federal government from hospice services every other Friday. The timing of period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $38.7 million in standby letters of credit as of March 31, 2017, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of March 31, 2017, we have approximately $246.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2017 and anticipate remaining in compliance throughout the foreseeable future.

The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including *qui tam* actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, *United States v. VITAS Hospice Services, LLC, et al.*, No. 4:13-cv-00449-BCW (the “2013 Action”). Prior to that date, the Company received various qui tam lawsuits and subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed. The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course. This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest. The defendants filed a motion to dismiss on September 24, 2013. On September 30, 2014, the Court denied the motion, except to the extent that claims were filed before July 24, 2002. On November 13, 2014, the government filed a Second Amended Complaint. The Second Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS. VITAS filed its Answer to the Second Amended Complaint on August 11, 2015. This case is in the discovery phase. The Company is not able to reasonably estimate the probability of loss or range of loss at this time. For additional procedural history of this litigation, please refer to our prior quarterly and annual filings. The net costs incurred related to U.S. v. Vitas and related regulatory matters were $2.2 million and $2.3 million for March 31, 2017 and 2016, respectively.

The Company and certain current and former directors and officers are defendants in a case captioned *In re Chemed Corp. Shareholder and Derivative Litigation*, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.), which was consolidated on February 2, 2015 and is covered by the Company’s commercial insurance.

-15-

On February 2, 2015, the Court appointed KBC Asset Management NV the sole lead plaintiff and its counsel, the sole lead and liaison counsel. On March 3, 2015, Lead Plaintiff KBC designated its Complaint as the operative complaint in the consolidated proceedings and defendants renewed a previously filed motion to dismiss those claims and allegations. The consolidated Complaint named fourteen individual defendants, together with the Company as nominal defendant. The Complaint alleges a claim for breach of fiduciary duty against the individual defendants for allegedly permitting the Company to submit false claims to the U.S. government. The Complaint seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. On May 12, 2016, the court issued a Memorandum Order granting Chemed’s motion to dismiss, and dismissing Lead Plaintiff KBC’s Complaint without prejudice to KBC’s opportunity to file within 30 days of the date of the court’s Order (June 13, 2016) an amended Complaint addressing the deficiencies in its duty of loyalty claim. Lead Plaintiff KBC did not file an amended Complaint within the time specified by the court.

However, on June 13, 2016, counsel for Chemed shareholder Michael Kvint filed a letter with the court requesting a two-week extension to file a motion to substitute Mr. Kvint as Lead Plaintiff, in place of Lead Plaintiff KBC and to file an amended Complaint. Alternatively, counsel for Mr. Kvint requested that any dismissal of the action be with prejudice to KBC only. On June 14, 2016, Chemed filed a reply letter with the court, reserving its rights to oppose any motion filed by Mr. Kvint and, if warranted, to oppose any other actions taken by Mr. Kvint to proceed with the action (including by filing an untimely amended Complaint). On June 21, 2016, the court entered an Oral Order providing Mr. Kvint until June 30, 2016 to file a Motion to Substitute and Motion for Leave to File an Amended Complaint. On that date, Mr. Kvint filed, under seal, a Motion to Substitute Plaintiff and File Amended Complaint, and attached a Proposed Amended Complaint. Mr. Kvint’s motion was fully briefed by the parties. The Court heard oral argument on Mr. Kvint’s motion on January 24, 2017. On January 25, 2017, Magistrate Judge Burke entered an Order requesting additional letter briefing on issues arising from Mr. Kvint’s motion. Pursuant to that Order, the parties have each submitted opening and reply letter briefing. Magistrate Judge Burke has not yet issued a recommendation or report on Mr. Kvint’s motion. For additional procedural history of this litigation, please refer to our prior quarterly and annual filings.

Jordan Seper, (“Seper”) a Registered Nurse at VITAS' Inland Empire program from May 12, 2014 to March 21, 2015, filed a lawsuit in San Francisco Superior Court on September 26, 2016. She alleged VITAS Healthcare Corp of CA (“VITAS CA”) (1) failed to provide minimum wage for all hours worked; (2) failed to provide overtime for all hours worked; (3) failed to provide a second meal period; (4) failed to provide rest breaks; (5) failed to indemnify for necessary expenditures; (6) failed to timely pay wages due at time of separation; and (7) engaged in unfair business practices. Seper seeks a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit. She seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre and post-judgment interest, and attorneys' fees and costs. Seper served VITAS CA with the lawsuit, Jordan A. Seper on behalf of herself and others similarly situated v. VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corp of CA, a business entity unknown; and DOES 1 to 100, inclusive; Los Angeles Superior Court Case Number BC 642857 on October 13, 2016.

On November 14, 2016, the Parties filed a Stipulation to transfer the venue of the lawsuit from San Francisco to Los Angeles. The Los Angeles Superior Court accepted transfer of the case on December 6, 2016. On December 16, 2016, VITAS CA filed its Answer and served written discovery on Seper.

Jiwan Chhina ("Chhina"), hired by VITAS as a Home Health Aide on February 5, 2002, is currently a Licensed Vocational Nurse for VITAS' San Diego program. On September 27, 2016, Chhina filed a lawsuit in San Diego Superior Court, alleging (1) failure to pay minimum wage for all hours worked; (2) failure to provide overtime for all hours worked; (3) failure to pay wages for all hours at the regular rate; (4) failure to provide meal periods; (5) failure to provide rest breaks; (6) failure to provide complete and accurate wage statements; (7) failure to pay for all reimbursement expenses; (8) unfair business practices; and (9) violation of the California Private Attorneys General Act. Chhina seeks to pursue these claims in the form of a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit. He seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre-judgment interest, and attorneys' fees and costs. Chhina served VITAS CA with the lawsuit, Jiwann Chhina v. VITAS Health Services of California, Inc., a California corporation; VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corporation of California, a Delaware corporation dba VITAS Healthcare, Inc.; and DOES 1 to 100, inclusive; San Diego Superior Court Case Number 37-2015-00033978-CU-OE-CTL on November 3, 2016. On December 1, 2016, VITAS filed its Answer and served written discovery on Chhina.

-16-

The Company is not able to reasonably estimate the probability of loss or range of loss for either of these lawsuits at this time.

The Company intends to defend vigorously against the allegations in each of the above lawsuits. Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

### Results of Operations

### Three months ended March 31, 2017 versus 2016 - Consolidated Results

Our service revenues and sales for the first quarter of 2017 increased 4.0% versus services and sales revenues for the first quarter of 2016. Of this increase, a $4.8 million increase was attributable to VITAS and $10.7 million increase was attributable to Roto-Rooter. The following chart shows the components of those changes (in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $10,686 | 5.0 |
| Continuous care | (4,304) | (11.6) |
| General inpatient | (1,594) | (6.2) |
| Roto-Rooter |  |  |
| Plumbing | 3,122 | 6.4 |
| Drain cleaning | 412 | 1.1 |
| Water restoration | 5,625 | 45.1 |
| Contractor operations | 1,167 | 11.8 |
| Other | 361 | 6.9 |
| Total | $15,475 | 4.0 |

The increase in VITAS’ revenues for the first quarter of 2017 versus the first quarter of 2016 was comprised of an average net Medicare reimbursement rate increasing approximately 1.6%, a 2.5% increase in days of care offset by acuity mix shift which negatively impacted revenue 2.4% as well as the 1.1% negative impact from having one less day in the quarter when compared to the prior year period.

Days of care during the quarter ended March 31 were as follows:

|  | Days of Care 2017 | 2016 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **1,380,548** | 1,335,617 | 3.4 |
| Continuous care | **45,417** | 50,970 | (10.9) |
| General inpatient | **33,985** | 38,249 | (11.1) |
| Total days of care | **1,459,950** | 1,424,836 | 2.5 |

Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first quarter of 2017 versus 2016 is attributable to an 8.3% increase in price and service mix shift offset by a 1.9% decrease in job count. Drain cleaning revenues for the first quarter of 2017 versus 2016 reflect a 6.1% increase in price and service mix shift offset by a 5.0% decrease in job count. Water restoration for the first quarter of 2017 versus 2016 increased 45.1% as a result of continued expansion of this service offering in all Roto-Rooter locations. Contractor operations increased 11.8% mainly due to their expansion into water restoration and other Roto-Rooter revenue increased 6.9%.

-17-

The consolidated gross margin was 29.7% in the first quarter of 2017 as compared with 28.7% in the first quarter of 2016. On a segment basis, VITAS’ gross margin was 21.5% in the first quarter of 2017 as compared with 21.0%, in the first quarter of 2016. The Roto-Rooter segment’s gross margin was 48.6% for the first quarter of 2017 compared with 47.6% in the first quarter of 2016.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

| SG&A expenses before market value adjustments of deferred compensation | Three months ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| plans, long-term incentive compensation, and OIG investigation expenses | **$63,732** | $59,937 |
| Long-term incentive compensation | **961** | (241) |
| Expenses related to OIG investigation | **2,150** | 2,336 |
| Impact of market value adjustments related to assets held in deferred |  |  |
| compensation trusts | **2,615** | (2,987) |
| Total SG&A expenses | **$69,458** | $59,045 |

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market value adjustments related to assets held in deferred compensation trusts for the first quarter of 2017 were up 6.3% when compared to the first quarter of 2016. This increase was mainly a result of the increase in variable expenses caused by increased revenue as well as normal salary increases in 2017.

Other operating expenses increased $873,000 in the first quarter of 2017 related to the closure of the programs in one state at Vitas. The expenses mainly include employee severance and the write-off of leasehold improvements for one in-patient unit. There were no other operating expenses in the first quarter of 2016.

Other income/(expense) - net comprise (in thousands):

| Market value adjustment on assets held in | Three months ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| deferred compensation trusts | **$2,615** | $(2,987) |
| Loss on disposal of property and equipment | **(236)** | (33) |
| Interest income | **85** | 97 |
| Other | **(1)** | (1) |
| Total other income/(expense) - net | **$2,463** | $(2,924) |

Our effective income tax rate was 30.5% in the first quarter of 2017 compared to 38.9% during the first quarter of 2016. The change in the effective income tax rate is a result of the adoption of ASU No. 2016-09 – Compensation – Stock Compensation which requires that the excess tax benefits from stock based compensation now be recorded in the income tax provision on the statements of income.

-18-

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| VITAS | Three months ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Expenses related to OIG investigation | **$(1,328)** | $(1,443) |
| Program closure expenses | **(513)** | - |
| Corporate |  |  |
| Excess tax benefits on stock compensation | **3,695** | - |
| Stock option expense | **(1,897)** | (1,621) |
| Long-term incentive compensation | **(608)** | 152 |
| Expenses related to securities litigation | **-** | (2) |
| Total | **$(651)** | $(2,914) |

### Three months ended March 31, 2017 versus 2016 - Segment Results

The change in after-tax earnings for the first quarter of 2017 versus the first quarter of 2016 is due to (in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $1,510 | 7.9 |
| Roto-Rooter | 1,604 | 12.3 |
| Corporate | 1,890 | 26.0 |
|  | $5,004 | 20.1 |

VITAS’ after-tax earnings were positively impacted in 2017 compared to 2016 by a $4.8 million increase in revenue, offset by a $2.4 million increase in cost of services provided and goods sold. After-tax earnings as a percent of revenue in the first quarter of 2017 were 7.3%, an increase of 0.4% over the first quarter of 2016.

Roto-Rooter’s after-tax earnings were positively impacted in 2017 compared to 2016 primarily by a $5.6 million revenue increase in Roto-Rooter’s water restoration line of business, a $3.1 million increase in plumbing revenue and a $2.0 million increase in all other revenue types. After-tax earnings as a percent of revenue at Roto-Rooter in 2017 were 11.8% as compared to 11.5% in 2016.

The improvement at Corporate is due mainly to the impact of the adoption of ASU 2016-09 which positively impacted the Company’s tax provision by approximately $3.7 million.

-19-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2017*

*(in thousands)(unaudited)*

| 2017 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $282,316 | $123,548 | $- | $405,864 |
| Cost of services provided and goods sold | 221,678 | 63,462 | - | 285,140 |
| Selling, general and administrative expenses | 24,294 | 33,460 | 11,704 | 69,458 |
| Depreciation | 4,778 | 3,984 | 131 | 8,893 |
| Amortization | 14 | 32 | - | 46 |
| Other operating expenses | 873 | - | - | 873 |
| Total costs and expenses | 251,637 | 100,938 | 11,835 | 364,410 |
| Income/(loss) from operations | 30,679 | 22,610 | (11,835) | 41,454 |
| Interest expense | (55) | (99) | (841) | (995) |
| Intercompany interest income/(expense) | 2,702 | 1,310 | (4,012) | - |
| Other income/(expense)—net | (80) | (72) | 2,615 | 2,463 |
| Income/(expense) before income taxes | 33,246 | 23,749 | (14,073) | 42,922 |
| Income taxes | (12,649) | (9,125) | 8,696 | (13,078) |
| Net income/(loss) | $20,597 | $14,624 | $(5,377) | $29,844 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(3,001) | $(3,001) |
| Long-term incentive compensation | - | - | (961) | (961) |
| Program closure expenses | (873) | - | - | (873) |
| Expenses related to OIG investigation | (2,150) | - | - | (2,150) |
| Total | $(3,023) | $- | $(3,962) | $(6,985) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,897) | $(1,897) |
| Long-term incentive compensation | - | - | (608) | (608) |
| Excess tax benefits on stock compensation | - | - | 3,695 | 3,695 |
| Program closure expenses | (513) | - | - | (513) |
| Expenses related to OIG investigation | (1,328) | - | - | (1,328) |
| Total | $(1,841) | $- | $1,190 | $(651) |

-20-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2016*

*(in thousands)(unaudited)*

| 2016 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $277,528 | $112,861 | $- | $390,389 |
| Cost of services provided and goods sold | 219,266 | 59,169 | - | 278,435 |
| Selling, general and administrative expenses | 24,783 | 29,807 | 4,455 | 59,045 |
| Depreciation | 4,781 | 3,501 | 142 | 8,424 |
| Amortization | 14 | 78 | - | 92 |
| Total costs and expenses | 248,844 | 92,555 | 4,597 | 345,996 |
| Income/(loss) from operations | 28,684 | 20,306 | (4,597) | 44,393 |
| Interest expense | (59) | (93) | (690) | (842) |
| Intercompany interest income/(expense) | 2,103 | 948 | (3,051) | - |
| Other income/(expense)—net | 41 | 23 | (2,988) | (2,924) |
| Income/(expense) before income taxes | 30,769 | 21,184 | (11,326) | 40,627 |
| Income taxes | (11,682) | (8,164) | 4,059 | (15,787) |
| Net income/(loss) | $19,087 | $13,020 | $(7,267) | $24,840 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,563) | $(2,563) |
| Long-term incentive compensation | - | - | 241 | 241 |
| Expenses related to securities litigation | - | - | (3) | (3) |
| Expenses related to OIG investigation | (2,336) | - | - | (2,336) |
| Total | $(2,336) | $- | $(2,325) | $(4,661) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,621) | $(1,621) |
| Long-term incentive compensation | - | - | 152 | 152 |
| Expenses related to securities litigation | - | - | (2) | (2) |
| Expenses related to OIG investigation | (1,443) | - | - | (1,443) |
| Total | $(1,443) | $- | $(1,471) | $(2,914) |

-21-

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2017 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $20,597 | $14,624 | $(5,377) | $29,844 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 55 | 99 | 841 | 995 |
| Income taxes | 12,649 | 9,125 | (8,696) | 13,078 |
| Depreciation | 4,778 | 3,984 | 131 | 8,893 |
| Amortization | 14 | 32 | - | 46 |
| **EBITDA** | 38,093 | 27,864 | (13,101) | 52,856 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (2,702) | (1,310) | 4,012 | - |
| Interest income | (70) | (15) | - | (85) |
| Program closure expenses | 873 | - | - | 873 |
| Expenses related to OIG investigation | 2,150 | - | - | 2,150 |
| Amortization of stock awards | 78 | 70 | 188 | 336 |
| Advertising cost adjustment | - | (274) | - | (274) |
| Stock option expense | - | - | 3,001 | 3,001 |
| Long-term incentive compensation | - | - | 961 | 961 |
| **Adjusted EBITDA** | $38,422 | $26,335 | $(4,939) | $59,818 |
|  |  |  |  | **Chemed** |
| **For the three months ended March 31, 2016** | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Net income/(loss)** | $19,087 | $13,020 | $(7,267) | $24,840 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 59 | 93 | 690 | 842 |
| Income taxes | 11,682 | 8,164 | (4,059) | 15,787 |
| Depreciation | 4,781 | 3,501 | 142 | 8,424 |
| Amortization | 14 | 78 | - | 92 |
| **EBITDA** | 35,623 | 24,856 | (10,494) | 49,985 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (2,103) | (948) | 3,051 | - |
| Interest income | (79) | (17) | (1) | (97) |
| Expenses related to OIG investigation | 2,336 | - | - | 2,336 |
| Amortization of stock awards | 131 | 81 | 327 | 539 |
| Expenses related to securities litigation | - | - | 3 | 3 |
| Advertising cost adjustment | - | (608) | - | (608) |
| Stock option expense | - | - | 2,563 | 2,563 |
| Long-term incentive compensation | - | - | (241) | (241) |
| **Adjusted EBITDA** | $35,908 | $23,364 | $(4,792) | $54,480 |

-22-

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Net income as reported | **$29,844** | $24,840 |
| Add/(deduct) after-tax cost of: |  |  |
| Excess tax benefits on stock compensation | **(3,695)** | - |
| Stock option expense | **1,897** | 1,621 |
| Expenses of OIG investigation | **1,328** | 1,443 |
| Long-term incentive compensation | **608** | (152) |
| Program closure expenses | **513** | - |
| Expenses related to securities settlements | **-** | 2 |
| Adjusted net income | **$30,495** | $27,754 |
| Diluted Earnings Per Share As Reported |  |  |
| Net income | **$1.78** | $1.45 |
| Average number of shares outstanding | **16,801** | 17,170 |
| Adjusted Diluted Earnings Per Share |  |  |
| Adjusted net income | **$1.82** | $1.62 |
| Adjusted average number of shares outstanding | **16,801** | 17,170 |

-23-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Homecare | **$225,536** | $214,850 |
| Inpatient | **23,923** | 25,517 |
| Continuous care | **32,857** | 37,161 |
| Total | **$282,316** | $277,528 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |
| Homecare | **79.9%** | 77.4% |
| Inpatient | **8.5** | 9.2 |
| Continuous care | **11.6** | 13.4 |
| Total | **100.0%** | 100.0% |
| Average daily census (days) |  |  |
| Homecare | **12,287** | 11,681 |
| Nursing home | **3,052** | 2,991 |
| Routine homecare | **15,339** | 14,672 |
| Inpatient | **378** | 421 |
| Continuous care | **505** | 560 |
| Total | **16,222** | 15,653 |
| Total Admissions | **17,563** | 16,868 |
| Total Discharges | **17,213** | 16,743 |
| Average length of stay (days) | **88.7** | 83.7 |
| Median length of stay (days) | **15.0** | 15.0 |
| ADC by major diagnosis |  |  |
| Cerebro | **19.7%** | 22.1% |
| Neurological | **34.4** | 31.2 |
| Cancer | **15.1** | 15.3 |
| Cardio | **16.6** | 17.3 |
| Respiratory | **7.9** | 7.9 |
| Other | **6.3** | 6.2 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Cerebro | **10.9** | 11.3% |
| Neurological | **22.1** | 20.9 |
| Cancer | **29.5** | 30.5 |
| Cardio | **15.1** | 15.5 |
| Respiratory | **11.7** | 10.9 |
| Other | **10.7** | 10.9 |
| Total | **100.0%** | 100.0% |
| Direct patient care margins |  |  |
| Routine homecare | **51.3%** | 52.1% |
| Inpatient | **5.9** | 5.7 |
| Continuous care | **15.6** | 15.1 |
| Homecare margin drivers (dollars per patient day) |  |  |
| Labor costs | **$58.64** | $56.72 |
| Combined drug, HME and medical supplies | **15.14** | 15.46 |
| Inpatient margin drivers (dollars per patient day) |  |  |
| Labor costs | **$369.99** | $338.73 |
| Continuous care margin drivers (dollars per patient day) |  |  |
| Labor costs | **$590.73** | $599.38 |
| Bad debt expense as a percent of revenues | **1.2%** | 1.3% |
| Accounts receivable -- Days of revenue outstanding- excluding unapplied Medicare payments | **35.9** | 38.3 |
| Accounts receivable -- Days of revenue outstanding- including unapplied Medicare payments | **24.9** | 36.8 |

-24-

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 601 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2017, the Company had $146.9 million of variable rate debt outstanding. For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 141 characters.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

-25-

Filed Apr 28, 2017.
Source: SEC EDGAR, the filing index for accession 0001157523-17-001278. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
